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We used high-resolution quantitative computed tomography
to study the microarchitecture of bone in patients with
chronic kidney disease on dialysis. We compared bone
characteristics in 56 maintenance hemodialysis (21 women,
14 post-menopausal) and 23 peritoneal dialysis patients (9
women, 6 post-menopausal) to 79 healthy men and women
from two cohorts matched for age, body mass index, gender,
and menopausal status. All underwent dual-energy X-ray
absorptiometry of the spine and hip to measure areal bone
mineral density, and high-resolution peripheral quantitative
computed tomography of the radius and tibia to measure
volumetric bone mineral density and microarchitecture.
When compared to their matched healthy controls, patients
receiving hemodialysis and peritoneal dialysis had a
significantly lower areal bone mineral density in the hip.
Hemodialysis patients had significantly lower total, cortical,
and trabecular volumetric bone mineral density at both sites.
Hemodialysis patients had significantly lower trabecular
volumetric bone mineral density and microarchitecture at the
tibia than the peritoneal dialysis patients. Overall, peritoneal
dialysis patients were less affected, their cortical thickness at
the distal tibia being the only significant difference versus
controls. Thus, we found more severe trabecular damage
at the weight-bearing tibia in hemodialysis compared to
peritoneal dialysis patients, but this latter finding needs
confirmation in larger cohorts.
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The physiological mechanisms regulating blood levels of
calcium, phosphate, vitamin D, and parathyroid hormone
(PTH) are often impaired in chronic kidney disease (CKD),
inducing both an increased incidence of vascular or soft
tissue calcifications and bone structural impairment. Skeletal
changes may occur years before the main clinical manifesta-
tions of bone disorders in CKD (i.e., pain and fractures).1
The risk of fracture exceeds that of the normal population in
both patients with pre-dialysis CKD and dialysis patients.
Indeed, a twofold increase in hip fracture risk in patients with
moderate-to-severe kidney disease and a fourfold increase in
dialysis men and women have been observed in the United
States.2,3 Moreover, young dialysis patients (age o45 years)
have a 80-fold higher relative risk of hip fracture than age-
and sex-matched controls subjects.3 Studies have identified
risk factors for fracture in dialysis patients that included
traditional risk factors (i.e., aging, female gender, lower body
weight, Caucasian race, impaired physical functioning,
tobacco exposure, and use of psychoactive drugs) and
specific comorbidities often associated to CKD such as
peripheral vascular disease, history of kidney transplant, and
either low or high PTH levels.4–7
The majority of studies of bone loss in CKD have been
performed with dual-energy X-ray absorptiometry (DXA) to
measure the areal bone mineral density (aBMD) at the spine
and proximal femur. However, even though this quantitative
technique is commonly used to screen individuals at risk of
fragility fracture in the general population, its value among
CKD patients is debated because of several technical
limitations, such as the overestimation of spine aBMD and
T-score because of aortic calcifications and the inability to
distinguish cortical (Ct) and trabecular (Tb) bone.8–10
Therefore, newer imaging modalities with improved spatial
resolution, such as peripheral quantitative computed tomo-
graphy (pQCT)11 and more recently high-resolution pQCT
(HR-pQCT) or magnetic resonance imaging, have been
developed, to allow a three-dimensional assessment of
microarchitecture, thus providing a more accurate estimation
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of bone quality and strength. HR-pQCT has been previously
described and has already been used to assess bone
microstructure in predialysis patients,12–15 but was rarely
used to investigate bone health in dialysis patients.
The aims of this single-center cross-sectional study were:
(1) to compare aBMD measured by DXA, volumetric BMD
(vBMD), and bone macro and microarchitecture parameters
assessed by HR-pQCT in maintenance hemodialysis (HD)
patients and peritoneal dialysis (PD) patients with healthy
controls, (2) to compare those results between the two
different types of dialysis groups, and (3) to examine
associations between bone data, and clinical and biochemical
variables in both dialysis groups.
RESULTS
Characteristics of study patients
HR-pQCT data at the tibia were not analyzed only in one
man, due to movement artefacts.
As shown in Table 1, HD patients were younger and less
likely to be Caucasian than PD patients.
As shown in Table 2, HD patients had a higher degree of
acidosis and greater concentrations of 25OH vitamin D than
PD patients.
The proportion of patients receiving a native vitamin D,
active vitamin D and calcium supplementation, a non-
calcium phosphate binder (sevelamer or lanthanum carbo-
nate), and cinacalcet–HCl treatment was not different between
dialysis groups (Table 2). About 20% of patients in both
groups had history of corticosteroid exposure and only two
HD patients and one PD patient were currently receiving
corticosteroids. No patient had history of bisphosphonates,
gonadal steroids, or aromatase inhibitors exposure.
DXA results in HD and PD patients
Total hip T-score was lower in HD and PD patients in
comparison with their matched controls, whereas there was
no difference at the lumbar spine (Table 3). No difference was
observed in PD vs. HD patients at both sites.
Macroarchitecture in HD and PD patients
At both sites, HD men and women had significant lower Ct
cross-sectional area, compared with their matched controls
(Tables 3 and 4). PD patients had significant lower Ct cross-
sectional area versus controls.
Microarchitecture in HD and PD patients
Figure 1 illustrates a distal tibial analysis (two-dimensional
slice) by HR-pQCT in a male control aged 34 years
(Figure 1a) and a male patient (Figure 1b) aged 26 years
who has been treated with hemodialysis for 13 months. He
suffered from hypertensive nephrosclerosis. His cortex is
thinand he had qualitative impairment of trabecular bone.
HD patients had both Tb and Ct bone impairment compared
with their matched controls. At the tibia, HD patients had
lower total, Ct and Tb vBMD, lower Ct.Th and Tb.Th, as well
as a lower Tb.N, compared with their matched controls
(Table 3). Moreover, they had higher Tb.Sp and Tb.SpSD
than controls. At the radius, HD patients had also lower total,
Ct and Tb vBMD, lower Ct.Th and Tb.Th than controls, and
the same trend than at the tibia was observed for Tb.N,
Tb.Sp, and Tb.SpSD, but it did not reach statistical
significance (Table 3). Bone parameters were analyzed
Table 1 | Characteristics of the dialysis patients
HD patients
(n=56)
PD patients
(n=23)
Age (years) 51±16* 60±16
Gender (M/F) 35/21 14/9
Caucasian race (%) 70* 96
Menopausal status for women (%) 67 67
Diabetes mellitus (%) 25 13
Weight (kg) 71±16 77±13
Height (cm) 168±10 167±8
Body mass index (kg/m2) 25.3±5.1 27.5±3.8
Main cause of kidney disease (n)
Chronic glomerulonephritis 12 6
Tubular and interstitial disease 5 1
Vascular disease 10 5
Diabetes 11 2
Polycystic kidney disease 6 7
Hereditary nephropathy 3 0
Others 9 2
Dialysis duration (months; median
(IQR))
20 (6–41) 14 (5–28)
Parathyroidectomy (%) 9 0
History of transplantation (%) 14 4
History of fragility fractures (%) 4 0
History of tobacco exposure (%) 57 52
Current smokers (%) 16 13
Abbreviations: F, female; HD, hemodialysis; IQR, interquartile range; M, male; PD,
peritoneal dialysis. *Po0.05 when comparing HD versus PD patients.
Table 2 | HD and PD patients’ serum values and medication
use
HD patients
(n=56)
PD patients
(n=23)
Calcium (mg/dl) 9.00±0.68 9.00±0.70
Phosphate (mg/dl, median (IQR)) 4.8 (4.9–6.4) 4.9 (4.2–6.3)
Bicarbonate (mol/l/l) 22.2±2.2* 24.2±3.5
CRP (mg/l, median (IQR)) 3.8 (1.6–10.8) 2.6 (1.8–4.4)
25(OH) vitamin D (ng/ml) 28±14* 19±11
1,25(OH)2 vitamin D (pmol/l) 50±27 38±19
BSAP (mg/l) 21.8±18.3 17.7±11.3
iPTH (pg/ml, median (IQR)) 299 (99–472) 320 (172–511)
iPTH o130 pg/ml (%) 29 13
iPTH (130–585) pg/ml (%) 52 70
iPTH 4585 pg/ml (%) 20 17
History of corticosteroid treatment 43
months (%)
20 22
Native vitamin D supplement (%) 30 22
Active vitamin D supplement (%) 43 50
Calcium supplement (%) 57 44
Phosphate binder (%) 55 61
Cinacalcet–HCl (%) 23 17
Abbreviations: BSAP, bone-specific alkaline phosphatase; CRP, C-reactive protein;
HD, hemodialysis; iPTH, second-generation intact parathyroid hormone; IQR,
interquartile range; PD, peritoneal dialysis.
*Po0.05 when comparing HD versus PD patients.
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according to the presence of an arteriovenous fistula used for
dialysis access. There was no statistical difference according to
the presence or absence of the vascular access.
The same trend was observed between PD patients and
their matched controls, but with a significant difference for
Ct.Th only at the distal tibia (10%; P¼ 0.055; Table 3).
In PD patients, after adjusting for age, race, serum
bicarbonate, and serum 25OH vitamin D, Tb microarchi-
tecture was less impaired than in HD patients, but this was
significant only at the tibia (Table 3).
Table 4 shows the detailed analyses of bone parameters
according to gender in HD patients. We did not analyze PD
patients according to gender because of the limited number
of patients. In HD patients, men bone parameters were more
homogenous than that those of women, especially for Tb
separation and distribution.
Association between macro and microarchitecture and
variables associated with CKD–MBD, in the HD cohort
Ct cross-sectional area at the radius (r¼0.31; Po0.05) and
at the tibia (r¼0.27; Po0.05) were negatively correlated
with dialysis duration, but were not correlated with Tb area.
Total vBMD at the radius (r¼0.31; Po0.05), Ct vBMD at
the radius, and the tibia (r¼0.38; Po0.01) (Figure 2) and
Ct.Th at the radius (r¼0.32; Po0.05) were negatively
correlated with dialysis duration but not Tb vBMD. At both
sites, Tb microarchitectural parameters, including Tb.N
(r¼0.37; Po0.01) along with Tb.Sp and Tb.SpSD
(r¼ 0.32 to 0.44; Po0.01) were associated with dialysis
duration. By contrast, hip aBMD and spine aBMD were not
associated with dialysis duration.
At the radius and tibia, Ct.Th (r¼0.28 and 0.30;
Pp0.05, respectively) was negatively correlated with serum
bone-specific alkaline phosphatase (BSAP), but the other HR-
pQCT parameters and DXA aBMD were not. Moreover, serum
BSAP was strongly correlated with others biological para-
meters: serum iPTH (r¼ 0.63; Po0.001), serum bicarbonate
(r¼ 0.31; Po0.05), serum calcium (r¼0.35; Po0.01), and
serum 1,25(OH)2 vitamin D (r¼0.26; P¼ 0.05). However,
there was no correlation with serum 25OH vitamin D.
Neither DXA nor HR-pQCT parameters were correlated
with serum iPTH. Nevertheless, iPTH was strongly correlated
Table 3 | Bone assessment by DXA and HR-pQCT in HD and PD patients and comparison with their controls, expressed as %
difference after total hip T-score adjustment for HR-pQCT variables
HD patients Controls
% Difference
after hip
T-score
adjustment PD patients Controls
% Difference
after hip
T-score
adjustment
%
Difference
HD vs. PD
DXA n=56 n=23
Lumbar spine T-score 0.8±1.4 0.7±1.3 0.9±1.3 0.2±1.3
Total hip T-score 1.4±1.4* 0.7±1.4 1.4±1.2E 0.8±1.1
HR-pQCT
Radius n=56 n=23
Total vBMD (mg HA/cm3) 274±74 317±63 13** 302±79 313±61 4 9
Cortical vBMD (mg HA/cm3) 808±72 857±55 6** 826±92 842±77 1 2
Trabecular vBMD (mg HA/cm3) 152±55 170±42 9* 169±45 172±41 6 10
Cortical thickness (mm) 660±242 785±184 14** 705±225 769±217 2 6
Trabecular number (mm1) 1.7±0.4 1.8±0.3 3 1.8±0.4 1.8±0.3 6 6
Trabecular thickness (mm) 72±15 79±12 7* 76±12 79±11 0 5
Trabecular separation (mm; median (IQR)) 494 (418–595) 476 (427–520) +4 431 (406–482) 490 (429–540) 4 +15
Trabecular distribution (mm; median (IQR)) 201 (173–268) 194 (169–217) +4 187 (173–236) 212 (168–243) 4 +7
Cortical cross-sectional area (mm2) 51±19 62±15 15** 55±17 61±18 4 7
Trabecular area (mm2) 270±62 263±68 4 272±76 270±64 2 1
Cortical perimeter (mm) 78±9 79±10 1 79±11 80±10 1 1
Tibia n=55 n=23
Total vBMD (mg HA/cm3) 253±61 302±55 16** 277±55 301±56 3 9
Cortical vBMD (mg HA/cm3) 844±74 873±57 3** 838±83 855±63 0 1
Trabecular vBMD (mg HA/cm3) 141±49 171±35 17** 166±39 172±38 1 15w
Cortical thickness (mm) 1025±301 1230±263 16 ** 1071±288 1253±327 10E 4
Trabecular number (mm1) 1.5±0.3 1.7±0.3 11** 1.8±0.5 1.7±0.3 8 17w
Trabecular thickness (mm) 77±19 84±11 7* 80±16 84±13 5 4
Trabecular separation (mm; median (IQR)) 595 (507–693) 502 (439–574) 14** 475 (443–584) 508 (433–585) 3 +25w
Trabecular distribution (mm; median (IQR)) 279 (223–314) 227 (196–255) 25** 214 (192–280) 240 (191–303) 6 +30w
Cortical cross-sectional area (mm2) 111±35 132±30 15** 118±32 137±37 9* 6
Trabecular area (mm2) 645±129 614±125 6 655±103 633±116 2 2
Cortical perimeter (mm) 109±10 108±10 1 111±8 110±9 0 2
Abbreviations: DXA, dual-energy X-ray absorptiometry; HD, hemodialysis; HR-pQCT, high-resolution peripheral quantitative computed tomography; IQR, interquartile range;
PD, peritoneal dialysis; vBMD, volumetric bone mineral density.
*Po0.05 in HD patients and in PD patients compared with controls.
**Po0.01 in HD patients compared with controls.
EP=0.055 in PD patients compared with controls.
wPo0.05 in HD patients compared with PD patients.
Kidney International (2012) 82, 581–588 583
S Pelletier et al.: Bone microarchitecture in dialysis patients o r ig ina l a r t i c l e
with BSAP, as described above, and negatively with serum
calcium (r¼0.33; Po0.01).
Serum 25OH vitamin D was only correlated with serum
1,25(OH)2 vitamin D (r¼ 0.58 P¼ 0.001).
Serum bicarbonate was correlated only with Tb vBMD at
the tibia (r¼ 0.29; Po0.05). In addition, diabetes had no
impact on bone density and bone microarchitecture values.
There was no relationship between serum albumin and any of
the bone parameters.
Association between macro and microarchitecture and
variables associated with CKD–MBD, in the PD cohort
Ct cross-sectional area was negatively correlated with dialysis
duration at the radius (r¼0.54; Po0.01) and at the tibia
(r¼0.52; Po0.05), but not with Tb area. At the tibia, Ct
vBMD (r¼0.39; P¼ 0.06) and Ct.Th (r¼0.40; P¼ 0.06)
tended to correlate negatively with dialysis duration, but not
aBMD.
At the tibia, Ct vBMD was negatively correlated with
serum BSAP (r¼0.49; Po0.05). Radius parameters by HR-
pQCT and DXA measurements were not correlated with
serum BSAP. The association between serum BSAP and serum
iPTH (r¼ 0.38; P¼ 0.08) did not reach statistical significance.
As observed in HD patients, serum iPTH was correlated with
neither DXA nor HR-pQCT parameters in PD patients.
Serum 25OH vitamin D was only correlated with serum
1,25(OH)2 vitamin D (r¼ 0.45; Po0.01).
Serum bicarbonate was not correlated with HR-pQCT
parameters or DXA aBMD.
Bone parameters, vitamin D threshold and vitamin D
therapies
In both dialysis groups, mean serum 25OH vitamin D was
o30 ng/ml, corresponding to a deficiency state (Table 2).
Thirty-five percent of HD and only 9% of PD patients had a
serum 25OH vitamin D430 ng/ml, 57% of HD and 65% of
Table 4 | Gender comparison of bone parameters assessed by DXA and HR-pQCT between HD men and women and their
controls, expressed as % difference after total hip T-score adjustment for HR-pQCT variables
HD male
patients Controls
% Difference
after
hip T-score
adjustment
HD female
patients Controls
% Difference
after
hip T-score
adjustment
DXA n=35 n=21
Lumbar spine T-score 0.8±1.4 0.7±1.3 0.8±1.5 0.7±1.4
Total hip T-score 1.5±1.4 1.1±1.0 1.2±1.3* 0.2±1.1
HR-pQCT
Radius n=35 n=21
Total vBMD (mg HA/cm3) 276±72 320±59 11** 271±79 311±70 14
Cortical vBMD (mg HA/cm3) 790±70 839±49 5** 838±65 887±52 6**
Trabecular vBMD (mg HA/cm3) 162±49 185±35 8* 134±60 146±43 8
Cortical thickness (mm) 666±249 791±195 12* 650±181 774±168 16*
Trabecular number (mm1) 1.8±0.3 1.9±0.3 0 1.5±0.4 1.7±0.3 9
Trabecular thickness (mm) 73±13 82±11 10* 70±19 71±11 0
Trabecular separation (mm; median
(IQR))
467 (411–568) 443 (410–500) 2 533 (456–674) 503 (459–564) 14
Trabecular distribution (mm; median
(IQR))
193 (163–237) 189 (166–215) 11 222 (189–318) 195 (176–226) 41
Cortical cross-sectional area (mm2) 55±21 67±15 13* 44±11 53±12 17*
Trabecular area (mm2) 302±46 297±54 2 216±47 205±46 7
Cortical perimeter (mm) 83±6 85±6 1 68±6 69±5 0
Tibia n=34 n=21
Total vBMD (mg HA/cm3) 256±64 310±57 15** 247±57 289±49 15**
Cortical vBMD (mg HA/cm3) 833±73 868±50 4* 861±75 882±67 3
Trabecular vBMD (mg HA/cm3) 151±51 181±35 14** 125±40 154±29 19*
Cortical thickness (mm) 1047±336 1283±285 15** 989±240 1144±199 14*
Trabecular number (mm1) 1.6±0.3 1.8±0.3 6 1.4±0.3 1.6±0.3 18**
Trabecular thickness (mm) 76±17 86±10 10* 78±22 79±10 1
Trabecular separation (mm; median
(IQR))
579 (451–610) 495 (423–552) 8* 651 (558–803) 529 (447–629) 22**
Trabecular distribution (mm; median
(IQR))
254 (208–296) 228 (199–254) 12* 288 (246–366) 223 (193–267) 45*
Cortical cross-sectional area (mm2) 120±39 143±29 13** 97±21 114±19 15**
Trabecular area (mm2) 715±93 665±111 8* 532±96 531±100 2
Cortical perimeter (mm) 115±6 113±7 2 99±7 100±8 0
Abbreviations: DXA, dual-energy X-ray absorptiometry; HD, hemodialysis; HR-pQCT, high-resolution peripheral quantitative computed tomography; IQR, interquartile range;
vBMD, volumetric bone mineral density.
*Po0.05 in HD patients compared with controls.
**Po0.01 in HD patients compared with controls.
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PD patients had a serum 25OH vitamin D ranging from 10 to
30 ng/ml, and 7% of HD and 26% of PD patients had a
serum 25OH vitamin D o10 ng/ml. No difference for age,
BMI, BSAP, aBMD, vBMD, and bone macro/microarchitec-
ture by HR-pQCT was observed between HD patients who
had serum 25OH vitamin D above or below 30 ng/ml, except
for iPTH and 1,25(OH)2 vitamin D. Indeed, mean serum
iPTH was greater (457±422 vs. 265±261 pg/ml; Po0.05)
and mean serum 1,25(OH)2 vitamin D was lower (39±16 vs.
67±36 ng/ml; Po0.001) in HD patients with serum 25OH
vitamin D p30 ng/ml than in those with serum 25OH
vitamin D 430 ng/ml. Only two PD patients had a serum
25OH vitamin D 430 ng/ml, precluding any meaningful
statistical analysis.
Moreover, supplementation with native, active vitamin D
or its analogs did not affect the statistical analyses results,
compared with patients not receiving such supplementation.
Bone parameters and iPTH targets based on the 2009 KDIGO
guidelines
Fifty-two percent of HD and 70% of PD patients had a serum
iPTH in the target range recommended by the KDIGO
guidelines (e.g., iPTH between two to nine times the upper
normal limit for the iPTH assay, here iPTH between 130 and
585 pg/ml), 29% of HD and 13% of PD patients had a serum
iPTH o130 pg/ml, and 20% of HD and 17% of PD patients
had a serum iPTH4585 pg/ml.16 No difference was observed
between iPTH groups in HD and PD patients for aBMD,
vBMD, and bone macro/microarchitecture.
DISCUSSION
The main finding of this study is that patients undergoing
maintenance HD had both significant Ct and Tb damage as
assessed by a three-dimensional non-invasive imaging
technique (HR-pQCT) at the radius and the tibia. The same
trend, but to a lesser extent, was observed in PD patients,
especially at the tibia, as only their Ct thickness and their Ct
cross-sectional area were lower than that of controls.
The two dialysis groups were not different for BMI,
dialysis duration, sex ratio, menopausal status, percentage of
diabetic patients, history of steroid exposure, medication
used to treat mineral and bone disorders, and serum bone
biomarkers, except for serum bicarbonate and serum 25OH
vitamin D. Mean serum bicarbonate was lower in HD
compared with PD group and this may have performed a role
in the Tb impairment we observed between HD and PD
patients, as suggested by the positive correlation found
between Tb vBMD and serum bicarbonate level at the tibia
site in HD patients. It is well known that chronic metabolic
acidosis alters the ionic composition of bone and increases
bone resorption, leading to bone fragility.17,18 However, no
data are currently available demonstrating a relation between
serum bicarbonate and Tb microarchitecture. Thus, the
clinical relevance of this difference is still debated.
The Tb density is an important factor of bone strength.
The underlying microstructural basis for reduction in Tb
bone density relies on the reduction in thickness and Tb
number.19 In our study, after adjusting for age, race, serum
bicarbonate, and serum 25OH vitamin D, Tb microarchi-
tecture was less impaired in PD patients than in HD patients,
but this was only significant at the tibia. This may suggest a
difference in bone fragility between HD and PD; however,
there is no clinical study to document this point.
Few studies were able to show significant association
between PTH serum levels and fractures.20,21 In our study,
there was no difference in bone architecture whether serum
iPTH and vitamin D were raised or not, both in HD and PD
patients. Thus, alterations of bone in HD and PD patients we
observed in the present study do not seem to be related to
serum iPTH and vitamin D evaluated once at the time of
bone measurements. One possible explanation could be that
serum iPTH and vitamin D can be rapidly modified by
ongoing mineral and bone treatments and thus do not reflect
the current bone status. Moreover, this may result from the
5.0 mm
5.0 mm
Figure 1 |Distal tibial analysis using high-resolution
peripheral quantitative computed tomography (HR-pQCT;
two-dimensional slice). (a) Result from a 34-year-old male
control. (b) Result from a 26-year-old hemodialysis patient,
undergoing hemodialysis for 13 months.
Kidney International (2012) 82, 581–588 585
S Pelletier et al.: Bone microarchitecture in dialysis patients o r ig ina l a r t i c l e
fact that macro/microarchitecture and Ct thickness are the
consequences of long-term PTH and vitamin D changes that
have occurred months of even years before bone parameters
measurements.
In this study, we noted a difference in hip aBMD but not
in spine aBMD assessed by DXA between HD and PD
patients and their controls. DXA is limited by the presence of
aortic calcifications, that are common in dialysis patients and
that may lead to an overestimation of spine aBMD and
T-score.22 This could explain the lack of difference in spine
T-score in HD and PD patients compared with controls,
whereas their hip T-score was lower. DXA has other technical
limitations. It only provides an areal analysis of a volume; its
resolution does not allow the distinction between Ct and Tb
bone compartments, whereas in CKD patients bone impair-
ment may differ across the two compartments. And lastly, it
does not allow an evaluation of bone microarchitecture,
whereas the 2000 NIH definition of osteoporosis highlighted
the need of evaluating both bone quantity and quality. Thus,
the 2009 KDIGO did not recommend the routine use of DXA
in advanced CKD with evidence of CKD–MBD.16
In previous studies, pQCT devices have been used to
assess volumetric bone density in predialysis patients, dialysis
patients, and in kidney transplant recipients.11,23–26 In a
cross-sectional study, Russo et al.24 demonstrated a reduction
in Ct vBMD in 39 HD patients in comparison with 67
controls, whereas there was no difference for Tb vBMD.
Moreover, Ct vBMD in HD patients correlated inversely with
age, duration of dialysis, as in our study (Figure 2), and also
with PTH. Hasegawa et al.25 confirmed those results
reporting a decreased Ct vBMD and Ct.Th in 83 HD
patients, whereas there were no difference in Tb vBMD in
comparison with 492 controls. The most significant predictor
of metabolic bone disease in their study was the dialysis
duration. In addition, increases in serum BSAP and iPTH
were correlated with decreases in Ct parameters. We also
report a negative correlation between serum BSAP and Ct.Th
at the radius and the tibia. In contrast to these findings,
Nickolas et al.27 and Tsuchida et al.11 reported that BSAP did
not correlate with Ct bone parameters in a predialysis CKD
population. We can hypothesize that Ct bone loss is more
important in dialysis patients compared with CKD patients
because of longer duration of CKD and chronic hyperpar-
athyroidism. It is therefore possible that the relationship
between BSAP and Ct parameters only appears for a more
severe Ct bone impairment, which occurs at the late CKD
stages or during maintenance dialysis.
In PD patients, Negri et al.28 reported a selective loss of Ct
vBMD and Ct.Th in 22 PD patients in comparison with 27
controls. In our study, Ct.Th measured at tibia by HR-pQCT
was also significantly lower in PD patients compared with
controls. These pQCT studies suggest selective Ct impairment
in dialysis patients. Nevertheless, pQCT cannot assess Tb
microarchitecture owing to its low resolution (350 mm),
which is inadequate to distinguish a trabeculae (100 mm
thickness in average).29 However, this measurement is now
possible with HR-pQCT having an isotropic resolution of
82 mm.30
Two bone studies using HR-pQCT were previously
reported in predialysis patients. Nickolas et al.12 compared
CKD patients with and without fragility fracture, and
reported association of low aBMD at multiple sites, vBMD,
and impaired microarchitecture with past fractures. They
suggested that both Ct and Tb impairment may contribute to
fracture susceptibility in the early course of CKD, whereas Ct
deficits seem to underlie propensity for fracture in patients
with CKD of longer duration.
Bacchetta et al.15 studied bone microarchitecture with
HR-pQCT at the radius and tibia in 70 CKD patients aged
70.8±8.5 years (46 men and 24 women, mean estimated
glomerular filtration rate¼ 34±12ml/min per 1.73m2 and
mean serum iPTH¼ 87±59 pg/ml) and compared their
outcomes with those of healthy controls comparable for age
and gender. This study demonstrated early Tb impairment at
the two sites in men and only at the tibia in women. Ct.Th in
men was also significantly decreased compared with healthy
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Figure 2 | Linear regression between dialysis duration (months) and cortical volumetric bone mineral density (vBMD; mg HA/cm3)
at the distal tibia in HD patients (open circle, r¼0.38, n¼ 56, Po0.01).
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controls. These results in CKD patients and ours in dialysis
patients could explain, at least partly, the higher risk of
fractures generally described in these patients.2,3 However,
further longitudinal studies could help to better define and
predict the risk fracture in the patients with renal failure.
Our study has limitations. The sample size of both HD and
PD patients was relatively small, and it was not possible to
separate patients by gender groups in PD patients. This study
was a cross-sectional study and did not allow the longitudinal
evaluation of fracture risk in a context of different metabolic
and hormonal effects of end-stage renal disease on bone
architecture. Moreover, it was difficult to assess the relation-
ships between biochemical measures and bone mass/archi-
tecture in a cross-sectional analysis. Technical limitations of
HR-pQCT can also be discussed. Indeed, its bone evaluation
excludes non mineralized matrix and thus cannot detect the
cases of osteomalacia. Therefore, we could not determine the
type of ROD with HR-pQCT as no bone biopsies were
performed for histomophometric analyses. At this point, these
two techniques are complementary: although some detailed
indications for bone histomorphometry have been validated
in the 2009 KDIGO international guidelines (i.e., unexplained
fractures, persistent bone pain, unexplained hypercalcemia, or
hypophosphatemia, possible aluminum toxicity and before
bisphosphonates therapy16), HR-pQCT could evaluate bone
fragility and microarchitecture in a novel noninvasive manner
in CKD and dialysis patients.31
In conclusion, this single-center cross-sectional study
showed an impairment in both Ct and Tb microarchitecture
in HD and PD patients using HR-pQCT and a more severe
Tb damage at the weight-bearing tibia in HD patients
compared with PD patients, but this latter finding needs
confirmation in larger cohorts.
MATERIALS AND METHODS
Patients
We have imaged 56 HD patients aged 25–80 years and 23 PD patients
aged 23–82 years. They were volunteers recruited from the
participating AURAL (Association pour l’Utilisation du Rein
Artificiel de la re´gion Lyonnaise, France) dialysis facilities and from
the HD center of Edouard Herriot University Hospital of Lyon,
France. Inclusion criteria were patients older than 18 years under-
going HD or PD since at least 90 days of maintenance therapy.
Patients with a history of malignancy or with bad general health,
limb-amputated patients, hospitalized patients, pregnant women,
nursing mothers, and patients who were not able to give informed
consent were excluded. Each patient was matched for age, gender,
body mass index, and menopausal status for women with one
control from a population-based prospective epidemiological cohort:
the STRAMBO and the OFELY cohort, respectively, for men and
women.32–34 STRAMBO is a prospective study of the determinants of
bone loss in 1149 men aged 19–85 years, recruited between February
2006 and February 2008, mainly randomly selected from the
affiliates of a large health insurance company (Mutuelle Ge´ne´rale
de l’Education Nationale) from the Rhoˆne district in France, with a
follow-up every 4 years. OFELY is a prospective study of the
determinants of bone loss in 1039 female volunteer, 31–89 years of
age, recruited between February 1992 and December 1993, randomly
selected from the affiliates of a large health insurance company
(Mutuelle Ge´ne´rale de l’Education Nationale) from the Rhoˆne
district in France, with an annual follow-up.
The baseline clinical data included patient’s anthropometry,
menopausal status for women, duration and date of dialysis,
comorbidities, and prescribed medications. Fifteen HD women had
a fracture history (13 fractures associated with trauma and 1 wrist
and hip fragility fracture, defined as a fracture associated with
trauma equivalent to or less than a fall from standing height). Five
PD patients had a history of fracture associated with trauma. The
dialysate calcium concentration was 1.5mmol/l in almost all HD
patients (96%). Medications were prescribed individually by each
physician without specific guideline recommendation.
This study was approved by a local independent ethical committee
(Comite´ de Protection des Personnes Lyon Sud Est IV), and all
dialysis patients gave informed consent after written information.
Laboratory measurements
Serum was collected before or after the HR-pQCT measurements,
within 2 weeks. Each serum was frozen at 80 1C and biological
data were measured at the same time and in the same laboratory to
improve reproducibility.
The following biological data were recorded in the dialysis patients:
serum levels of calcium, phosphorus, bicarbonate, ultrasensitive
C-reactive protein, intact PTH (iPTH) measured with a second-
generation assay (Roche Elecsys, Roche Diagnosis, Mannheim,
Germany; normal values 15–65pg/ml), 25OH vitamin D, and
1,25(OH)2 vitamin D with radioimmunological assays (DIASORIN-
RIA, Diasorin Diagnosis, Saluggia, Italy; respective range of desirable
values 30–80ng/ml and 43–148pmol/l). Serum BSAP was measured
with Ostase assay (Beckman Coulter, Fullerton, CA; normal values
4–21mg/l).
Dual-energy X-ray absorptiometry
Lumbar spine (L1–L4) aBMD and total hip aBMD were measured
using a Hologic QDR 4500 densitometer for control women from
the OFELY study and a Hologic Discovery densitometer for control
men from the STRAMBO study and for dialysis patients (Hologic,
Bedford, MA).
High-resolution peripheral quantitative computed
tomography
vBMD (total vBMD, Ct, and TbT vBMD), microarchitecture (Ct
(Ct.Th) and Tb (Tb.Th) thickness, Tb number (Tb.N), separation
(Tb.Sp) and heterogeneity of the Tb network (Tb.SpSD), and
macroarchitecture parameters (Ct cross-sectional area, Ct perimeter,
and Tb area)) at the ultradistal radius, and tibia were measured
using HR-pQCT (XtremeCT; Scanco Medical AG, Bru¨ttisellen,
Switzerland). This system enables the simultaneous acquisition of a
stack of 110 parallel slices with a nominal resolution (voxel size) of
82 mm, leading to a three-dimensional representation of B9mm in
the axial direction.30 The following settings were used: effective
tension of 60 kVp, X-ray tube current of 900 mA, and matrix size of
1536*1536. It induces low radiation exposure (effective dose of 3 mSv
per measurement) with an acquisition time of 3min. It has an
excellent precision for both vBMD (0.7–1.5%) and a satisfying
precision for structural parameters (1.5–4.4%).30
Exams were performed at the nondominant radius and tibia,
however, when there was a history of fractures at these sites the scan
was done on the controlateral side.
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Statistical analysis
The main analysis consisted of a pairwise comparison of dialysis
patients with their matched controls for hip and spine aBMD and
vBMD, and macro and microarchitecture at the radius and tibia
after adjustment on T-score by DXA at the hip. We also compared
those parameters between dialysis groups (HD vs. PD) and we
analyzed correlations between bone data and clinical variables.
Statistical analyses were conducted using the SPSS software
Version 16.0 (Chicago, IL). Pairwise comparisons were performed
using Student’s t test or Wilcoxon signed rank test, depending on the
distribution of variables. Dichotomous variables were compared
using the Pearson’s w2 test. Correlations between quantitative
variables were assessed by the Pearson’s or the Spearman’s
correlation test, depending on the distribution of variables. Analysis
of covariance was conducted to take into account the effect of age,
race, serum bicarbonate, and serum 25OH vitamin D on the relation
between Tb microarchitecture and both dialysis groups. All
statistical tests were performed at the two-sided 0.05 level of
significance. Data are presented as mean±s.d., or median (inter-
quartile range) when variables were not normally distributed.
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